Research progress in inhibiting neovascularization of lung cancer and its clinical application
ZHANG Rui-lian1 ZHANG Qing2▲
1.Graduate School of Inner Mongolia Medical University,Inner Mongolia Autonomous Region,Hohhot 010010,China;2.Department of Respiratory Medicine,Affiliated Hospital of Inner Mongolia Medical University,Inner Mongolia Autonomous Region,Hohhot 010010,China
Abstract:Angiogenesis can seriously affect the occurrence and development of tumors.In recent years,with the development of molecular biology,targeting angiogenesis has become a research hotspot for the treatment of non-small cell lung cancer(NSCLC).Blocking the blood supply of tumor cells,making the cells in a state of hypoxia and lack of nutrients,is an effective means to inhibit the growth and proliferation of tumors.Targeting tumor angiogenesis as a target has become a research hotspot,however,the Angiogenesis is extremely complex,and single target blocking therapy often does not solve the underlying problem.Future anti-vascular therapies will focus on multi-target combined blockade.This article reviews the role of several regulatory factors related to tumor angiogenesis and their clinical applications,aiming to provide a reference for the clinical research of lung cancer.
张瑞连;张卿. 抑制肺癌新生血管及其临床应用的研究进展[J]. 中国当代医药, 2018, 25(26): 36-38.
ZHANG Rui-lian;ZHANG Qing. Research progress in inhibiting neovascularization of lung cancer and its clinical application. 中国当代医药, 2018, 25(26): 36-38.
Takahashi T,Kozaki K,Yatabe Y,et al.Increased expression of COX-2 in the development of human lung cancers[J].J Environ Pathol Toxicol Oncol,2002,21:177-181.
[10]
Kim HS,Youm HR,LeeJS,et al.Correlation between cyclooxygenase-2 and tumor angiogenesis innon—small cell lung caneer[J].Lung Cancer,2003,42:163-179.
[11]
Howe LR,Dannenberg AJ.A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer[J].Semin Oncol,2002,29(11):111-119.
Cianchi F,Cortesini C,Bechi P,et al.Up-regulation of cyclooxygen-ase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer[J].Gastroenterology,2001,121 (6): 1339-1347.
[15]
Liu R,Xu KP,Tan GS.Cyclooxygenase-2 inhibitors in lung Cancer treatment:bench to bed[J].Eur J Pharmacol,2015,769:127-133.
Reckamp KL,Koczywas M,Cristea MC,et al.Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer[J].Cancer,2015,121(18):3298-3306.
[24]
Lippman SM,Gibson N,Subbaramaiah K,et al.Combined targeting of the epidermal growth factor receptor and cyclooxy-genase-2 pathways[J].Clin Cancer Res,2005,11(17):6097-6099.